15, December 2015

Over 70 Lupus Specialists Gather in Paris for Lupuzor’s™ Phase III Investigators Meeting

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to provide a summary of the Investigators Meeting which was held in Paris on 11th/12th...

Click here for more details

07, December 2015

Lupuzor™ Pivotal Phase III Trial Recruiting First US Lupus Patients

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor&...

Click here for more details

04, November 2015

Lupuzor™ Phase III Pivotal Trial Update

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to provide an update on the progress of its Phase III clinical trial of Lupuzor™,...

Click here for more details

23, October 2015

Board Change

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that Ajay Agrawal has stepped down as Non-Executive Director with immediate effect.Tim M...

Click here for more details

30, September 2015

Tim McCarthy Appointed as Non-executive Chairman

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce the appointment of Tim McCarthy as Non-executive Chairman, with immediate e...

Click here for more details

30, September 2015

Interim Results Announcement for the six months ended 30 June 2015

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2015 (the “Perio...

Click here for more details

29, July 2015

Richard Warr

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company is truly saddened to announce that Richard Warr, Chairman, passed away late last week. Dimitri...

Click here for more details

27, July 2015

Term Sheet signed with US Investor to secure up to US$14 Million Funding For LUPUZOR™

ImmuPharma has also signed a Term Sheet with a US investor for a proposed private placement to fund the clinical trial. The initial instalment of funding consists of a convertible loan of US$2,000,000 plus additional capital of up t...

Click here for more details

27, July 2015

ClinicalTrials.Gov registration of LUPUZOR™ Pivotal Phase III Trial

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company is delighted to announce that registration with the U.S. National Institutes of Health - ClincialTr...

Click here for more details

25, June 2015

Lupuzor’s Founder, Dr Slyviane Muller – Awarded Medal of Innovation from CNRS for Lupuzor™

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company is delighted to announce that Dr Sylviane Muller the key inventor of Lupuzor™ and Research Di...

Click here for more details

29, May 2015

ANNUAL GENERAL MEETING: 2015

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were duly passed. A sum...

Click here for more details

07, May 2015

Notice of Annual General Meeting: 29 May 2015

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company confirms that the Annual Report and Accounts for the year ended 31 December 2014 will be posted to...

Click here for more details

30, April 2015

Preliminary Results Announcement for the year ended 31 December 2014

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce its preliminary audited results for the year ended 31 December 2014.Key Hig...

Click here for more details

30, April 2015

Dr Stéphane Méry Appointed as Non-Executive Director

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce the appointment of Dr Stéphane Méry as non-executive director.Dr Stéphan...

Click here for more details

11, February 2015

Cancer Update: IPP-204106

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, provides an update on its lead Cancer programme – IPP-204106.As previously stated, the Phase...

Click here for more details

27, January 2015

Advance Assurance Received from H M Revenue and Customs Regarding “Enterprise Investment Scheme” Status

ImmuPharma PLC (AIM: IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces that it has received advance assurance from H M Revenue and Customs that it would qu...

Click here for more details

22, January 2015

Landmark Collaboration Agreement & Commencement of Pivotal Phase III Lupuzor™ Study with Simbec-Orion

Deal provides powerful validation for Lupuzor™ImmuPharma PLC (AIM: IMM) (“ImmuPharma”) and Simbec-Orion Group Limited (“Simbec-Orion”) announce that they have today entered into a Collaboration Agreemen...

Click here for more details